Table 2.

Macaques given four (study 1) or seven treatments (study 2) with stable nucleic acid-lipid particles containing Zaire Ebola virus (ZEBOV) small interfering RNAs (siRNAs) after ZEBOV challenge

	Adverse events on days 1–35 after ZEBOV challenge	Status
Study 1
Animal 1	Anorexia (days 7–9), lymphopenia (day 6), >5-fold increase in AST (day 10)	Survived
Animal 2	Fever (day 6), mild rash (days 8,11, and 12), moderate rash (days 9 and 10), depression (days 7–11), anorexia (days 7–11), diarrhoea (day 12), lymphopenia (days 6 and 14), thrombocytopenia (day 6), 2–3-fold increase in ALP (day 10), 2–3-fold increase in ALT (day 10), 2–3-fold increase in AST (day 6), >5-fold increase in AST (day 10), >5-fold increase in GGT (day 10)	Survived
Animal 3	Mild rash (days 6–10), depression (days 6–-10), anorexia (days 6–10), bleeding at venepuncture site (day 10), recumbency (day 10), thrombocytopenia (day 6), 2–3-fold increase in ALP (day 6), >5-fold increase in ALP (day 10), 4–5-fold increase in ALT (day 10), 2–3-fold increase in AST (day 3), >5-fold increase in AST (days 6 and 10), >5-fold increase in BUN (day 10), >5-fold increase in creatinine (day 10), >5-fold increase in GGT (day 10)	Died on day 10
Control 1*	Mild rash, anorexia, and depression on day 5	Died day 6
Study 2
Animal 4	Thrombocytopenia (days 6 and 10), 4–5-fold increase in AST (day 6)	Survived
Animal 5	>5-fold increase in AST (day 6), 2–3-fold increase in AST (day 10)	Survived
Animal 6	Fever (day 10), lymphopenia (day 6), thrombocytopenia (days 6, 10, and 14), 2–3-fold increase in AST (day 10)	Survived
Animal 7	Fever (day 10), lymphopenia (day 6), thrombocytopenia (day 6), >5-fold increase in AST (day 10)	Survived
Control 2†	Fever (day 6), moderate rash (day 10), recumbency (day 10), thrombocytopenia (day 6) 2–3-fold increase in ALT (day 6), >5-fold increase in ALT (day 10), >5-fold increase in AST (days 6 and 10), >5-fold increase in BUN (day 10), 2–3-fold increase in creatinine (day 10)	Died on day 10

Fever was defined as a temperature that was 2·5° greater than baseline temperature or at least 1·5° greater than baseline temperature, and at least 103·5°F. Mild rash was defined as focal petechiae covering less than 10% of skin. Moderate rash was defined as petechiae covering between 10% and 40% of skin. Severe rash was defined as petechiae or ecchymoses covering more than 40% of skin. Lymphopenia was defined as at least a 35% reduction in numbers of lymphocytes; and thrombocytopenia was defined as at least a 35% reduction in numbers of platelets. AST=aspartate aminotransferase. ALP=alkaline phosphatase. ALT=alanine aminotransferase. GGT=γ glutamyltransferase. BUN=blood urea nitrogen.

^*Not given any siRNAs.

^†Given seven treatments with non-specific siRNAs.